Gene Signature Identifies Patients Benefiting from Anthracycline in HR+/HER2– Breast Cancer

New research indicates that a specific 70-gene signature (MammaPrint) can predict which patients with stage I to III HR+/HER2– breast cancer will benefit from anthracycline-based chemotherapy regimens. Patients classified as high risk 2 by the gene signature showed improved invasive disease-free survival with anthracycline-containing treatments, suggesting genomic risk, rather than clinical features alone, is a predictive biomarker.

Context

HR+/HER2– breast cancer is a common subtype that often requires chemotherapy. Traditionally, treatment decisions have relied on clinical features, which may not accurately predict individual responses. The introduction of the 70-gene signature, MammaPrint, provides a new genomic tool for assessing patient risk and treatment suitability.

Why it matters

This research offers a significant advancement in personalizing treatment for HR+/HER2– breast cancer patients. By identifying a specific gene signature that predicts response to anthracycline chemotherapy, it can lead to more effective treatment plans. This could improve patient outcomes and reduce unnecessary exposure to ineffective therapies.

Implications

If widely adopted, this gene signature could change how oncologists approach treatment decisions for HR+/HER2– breast cancer. Patients identified as high risk may receive more targeted therapies, potentially improving survival rates. Conversely, those deemed low risk may avoid aggressive treatments, leading to reduced side effects and healthcare costs.

What to watch

Ongoing clinical trials may further validate the use of the MammaPrint gene signature in diverse patient populations. Researchers will likely explore its application in other chemotherapy regimens beyond anthracycline. Monitoring the adoption of this genomic test in clinical settings will be crucial for understanding its impact on treatment practices.